The Boehringer family stands behind Boehringer Ingelheim, one of the world’s largest privately owned pharmaceutical companies. Unlike publicly traded drug manufacturers, the company operates with a long-term research horizon shaped by family ownership.
Founded in 1885 in Germany, Boehringer Ingelheim initially focused on chemical production before transitioning into pharmaceuticals. The family’s commitment to reinvesting profits into research enabled breakthroughs in respiratory medicine, cardiology and animal health.
The company invests billions annually in R&D, often prioritizing innovation over short-term profitability. This strategy has allowed Boehringer Ingelheim to remain competitive despite intense pressure from global pharmaceutical giants.
Family ownership ensures continuity, conservative financial management and insulation from market volatility. Governance structures balance professional management with family oversight, maintaining stability across generations.
